Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gamma-aminobutyric acid + piroxicam is a combination drug containing gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the central nervous system, and piroxicam, a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. Piroxicam works by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever[1][2]. The addition of GABA may theoretically augment analgesia by modulating synaptic transmission, although the specific pharmacodynamic synergy of this combination is not well-documented in the available literature. The combination is indicated for the relief of pain and inflammation in chronic conditions such as rheumatoid arthritis and osteoarthritis[3]. This product is formulated as a kit for oral administration and is intended for once daily dosing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gamma-aminobutyric acid + piroxicam.